EUVIMEDEUVIMED entdecken
StudienprotokollOpen Access

Outcome of ALL With ALL-BFM-95 Protocol in Nepal

Bishesh Sharma Poudyal iD, Bishal Paudel, Sampurna Tuladhar, Samir Neupane, Kushal Bhattarai, Utsav Joshi iD

JCO Global Oncology · 2023

DOI: 10.1200/go.22.00408 ↗

Kurz gefasst

Studienprotokoll in der Zeitschrift JCO Global Oncology, 2023. Verfasst von Bishesh Sharma Poudyal und 5 weiteren Autor:innen. Beteiligte Einrichtung: Clinical Hematology and Bone Marrow Transplant Unit, Civil Service Hospital, Kathmandu, Nepal. Hauptthemen laut MEDLINE: Precursor Cell Lymphoblastic Leukemia-Lymphoma. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 14 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE Data on survival outcomes in patients with acute lymphoblastic leukemia (ALL) originating from Nepal are limited. We aim to present the real-world data on treatment outcomes of patients with de novo ALL treated with pediatric ALL-Berlin-Frankfurt-Muenster (BFM)-95 protocol in Nepal. PATIENTS AND METHODS We used the medical records of 103 consecutive patients with ALL treated in our center from 2013 to 2016 to evaluate the overall survival (OS) and relapse-free survival (RFS) and analyzed the effects of clinicopathologic factors on survival outcomes in patients with ALL. RESULTS The 3-year OS and RFS in the entire cohort was 89.4% (95% CI, 82.1 to 96.7) and 87.3% (95% CI, 79.8 to 94.7), with a mean OS and RFS of 79.4 months (95% CI, 74.2 to 84.5) and 76.6 months (95% CI, 70.8 to 82.4), respectively. Patients with prednisone good response (PGR) showed better mean OS and RFS, whereas complete marrow response on day 33 was associated with better mean OS alone. Patients with Philadelphia (Ph)-positive ALL showed worse mean RFS compared to those with Ph-negative status. On multivariate analysis, PGR (hazard ratio [HR], 0.11; 95% CI, 0.03 to 0.49; P = .004) and sagittal vein thrombosis (SVT; HR, 5.95; 95% CI, 1.30 to 27.18; P = .02) were the only independent predictors of OS and RFS, respectively. Adverse events on BFM-95 protocol included SVT (4.9%), peripheral neuropathy (7.8%), myopathy (20.4%), hyperglycemia (24.3%), intestinal obstruction (7.8%), avascular necrosis of femur (6.8%), and mucositis (46%). CONCLUSION BFM-95 protocol appears to be a safe and effective strategy in adolescent and young adults and adult Nepalese population with ALL with a low toxicity profile.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Precursor Cell Lymphoblastic Leukemia-LymphomaAntineoplastic Combined Chemotherapy ProtocolsPrednisoneAdolescentChildMercaptopurineHumansAsparaginaseTreatment OutcomeCytarabineYoung AdultCyclophosphamidePrednisoloneVincristineDaunorubicinNepal

Substanzen

PrednisoneAsparaginaseCyclophosphamideCytarabineDaunorubicinPrednisoloneVincristineMercaptopurine

Autor:innen und Institutionen

  • Clinical Hematology and Bone Marrow Transplant Unit, Civil Service Hospital, Kathmandu, Nepal.
  • Department of Pathology, Civil Service Hospital, Kathmandu, Nepal.
  • Department of Biochemistry, Karnali Academy of Health Sciences, Jumla, Nepal.
  • Department of Internal Medicine, Rochester General Hospital, New York, NY.

ORCID-Profile: Bishesh Sharma Poudyal, Utsav Joshi

Zitieren

APA

Sharma Poudyal, B., Paudel, B., Tuladhar, S., Neupane, S., Bhattarai, K., & Joshi, U. (2023). Outcome of ALL With ALL-BFM-95 Protocol in Nepal. JCO Global Oncology. https://doi.org/10.1200/go.22.00408

Vancouver

Sharma Poudyal B, Paudel B, Tuladhar S, Neupane S, Bhattarai K, Joshi U. Outcome of ALL With ALL-BFM-95 Protocol in Nepal. JCO Global Oncology. 2023. doi:10.1200/go.22.00408

BibTeX
@article{SharmaPoudyal2023,
  author = {Sharma Poudyal, Bishesh and Paudel, Bishal and Tuladhar, Sampurna and Neupane, Samir and Bhattarai, Kushal and Joshi, Utsav},
  title = {Outcome of ALL With ALL-BFM-95 Protocol in Nepal},
  journal = {JCO Global Oncology},
  year = {2023},
  doi = {10.1200/go.22.00408}
}
Kostenlos starten →